These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
    Author: Andrews HN, Habibi G, Kucab JE, Dunn SE.
    Journal: Breast Cancer Res Treat; 2005 Nov; 94(1):47-52. PubMed ID: 16172791.
    Abstract:
    Elevated urokinase-type plasminogen activator (uPA) expression in breast tumors predicts poor survival. We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment. Celecoxib also inhibited cell viability (12.5 and 25 microM) and induced G2M arrest (25 microM). Therefore, celecoxib therapy for uPA positive breast cancer should be explored.
    [Abstract] [Full Text] [Related] [New Search]